WARNING

While Ibritumomab injection can be effective in treating certain types of non-Hodgkin’s lymphoma (NHL), it does carry some risks and potential side effects. Here is a brief overview of the risks associated with Ibritumomab injection:

• Infusion reactions: During or shortly after the infusion of Ibritumomab, some individuals may experience infusion-related reactions, including fever, chills, nausea, vomiting, headache, dizziness, itching, rash, and difficulty breathing. These reactions can range from mild to severe and may require medical attention.
• Bone marrow suppression: Ibritumomab can affect the bone marrow’s ability to produce new blood cells, leading to a decrease in white blood cells, red blood cells, and platelets. This can result in an increased risk of infection, anemia, and bleeding. Regular blood tests are necessary to monitor blood cell counts during treatment.
• Serious infections: Since Ibritumomab can reduce the number of white blood cells, which are essential for fighting infections, there is an increased risk of developing serious infections. Patients should promptly report any signs of infection, such as fever, sore throat, or persistent cough, to their healthcare provider.
• Radiation-related risks: Ibritumomab contains a radioactive substance, yttrium-90. While steps are taken to minimize radiation exposure to healthy tissues, there is still a potential risk of radiation-related side effects. These may include low blood counts, fatigue, and an increased risk of developing certain cancers, particularly myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
• Hypersensitivity reactions: Some individuals may experience allergic or hypersensitivity reactions to Ibritumomab. Signs of a severe allergic reaction may include difficulty breathing, chest tightness, swelling of the face or throat, and hives. Immediate medical attention is necessary if such reactions occur.
• Other side effects: Additional side effects associated with Ibritumomab can include fatigue, stomach discomfort, diarrhea, muscle or joint pain, and skin reactions.

It’s important to note that the risks and side effects can vary from person to person, and not everyone will experience all of these effects. Healthcare providers closely monitor patients receiving Ibritumomab and take necessary precautions to minimize risks. It’s crucial to discuss any concerns or questions with a healthcare professional before starting treatment.

Why is this medication prescribed?

Ibritumomab injection is a prescription medication used for the treatment of certain types of non-Hodgkin’s lymphoma (NHL), specifically follicular lymphoma and transformed follicular lymphoma. It is typically prescribed when other treatments have been unsuccessful or are no longer effective. Ibritumomab belongs to a class of medications called radioimmunotherapies. It combines a monoclonal antibody called rituximab with a radioactive substance called yttrium-90. The rituximab component specifically targets and binds to a protein called CD20 found on the surface of B cells, which are cancerous cells in NHL. This allows the radioactive yttrium-90 to directly deliver radiation to the cancerous cells, thereby destroying them. Ibritumomab injection is often used as part of a comprehensive treatment plan for NHL and is typically administered in conjunction with other therapies such as chemotherapy. The specific dosage and treatment regimen will depend on individual factors, including the stage and characteristics of the lymphoma, as well as the patient’s overall health.

How should this medicine be used?

Ibritumomab injection is a medication that is administered by a healthcare professional, typically in a hospital or clinical setting. Here are some general guidelines for the use of Ibritumomab:

• Pre-treatment evaluation: Before starting Ibritumomab treatment, your healthcare provider will conduct various tests and assessments to determine if it is appropriate for you. This may include blood tests, imaging scans, and evaluation of your overall health.
• Dosage and administration: Ibritumomab is administered as an intravenous (IV) infusion. The infusion consists of two parts: a rituximab infusion followed by the Ibritumomab-yttrium-90 infusion. The rituximab infusion is usually given a week before the Ibritumomab infusion to help target the CD20 protein on the cancer cells.
• Radioprotective measures: To minimize radiation exposure to healthy tissues, certain radioprotective measures may be taken before and after the Ibritumomab infusion. This may involve drinking plenty of fluids, taking diuretics to promote urinary excretion of radioactivity, and following guidelines for radiation safety at home.
• Monitoring and follow-up: During and after treatment, your healthcare provider will closely monitor your blood cell counts and overall health. Regular follow-up appointments and blood tests will be scheduled to assess treatment response and manage any potential side effects.
• Safety precautions: Due to the radioactive nature of Ibritumomab, it is important to follow safety precautions as advised by your healthcare provider. These may include guidelines for handling bodily fluids, avoiding close contact with pregnant women or small children, and proper disposal of items that come into contact with your bodily fluids.

It’s crucial to strictly adhere to the treatment plan and follow all instructions provided by your healthcare provider. They will determine the appropriate dosage, infusion schedule, and radioprotective measures based on your specific condition. If you have any questions or concerns regarding the administration of Ibritumomab, it’s important to discuss them with your healthcare professional.

Other uses for this medicine

Ibritumomab injection is primarily used for the treatment of certain types of non-Hodgkin’s lymphoma (NHL), specifically follicular lymphoma and transformed follicular lymphoma. However, it is important to note that Ibritumomab is not approved for other uses. Its effectiveness and safety have been specifically studied and established for the treatment of NHL.

What special precautions should I follow?

As for special precautions associated with Ibritumomab injection, here are some important considerations:

• Pregnancy and breastfeeding: Ibritumomab can cause harm to an unborn baby, so it is generally not recommended during pregnancy unless the potential benefits outweigh the risks. It is also not known whether Ibritumomab passes into breast milk, so breastfeeding is typically not recommended while undergoing treatment.
• Allergies: Before receiving Ibritumomab, it is important to inform your healthcare provider about any known allergies or hypersensitivity reactions to medications, including rituximab or other components of Ibritumomab.
• Infections: Ibritumomab can suppress the immune system, making you more susceptible to infections. It is important to inform your healthcare provider about any existing infections, recent infections, or a history of recurring infections. Promptly report any signs or symptoms of infection during and after treatment.
• Bone marrow suppression: Ibritumomab can cause a decrease in blood cell counts, including white blood cells, red blood cells, and platelets. Regular blood tests are necessary to monitor these levels. Precautions may be taken to reduce the risk of bleeding, such as avoiding certain medications or activities that can increase the likelihood of injury.
• Radiation precautions: Due to the radioactive nature of Ibritumomab, it is important to follow safety precautions as advised by your healthcare provider. These precautions may involve limiting close contact with pregnant women or small children, following radiation safety guidelines at home, and proper disposal of items that come into contact with your bodily fluids.

It’s important to discuss your medical history, current medications, and any specific concerns with your healthcare provider before starting Ibritumomab treatment. They can provide you with personalized advice and recommendations based on your individual circumstances.

What special dietary instructions should I follow?

There are no specific dietary instructions associated with Ibritumomab injection. However, it is important to maintain a healthy and balanced diet to support your overall well-being during treatment. A nutritious diet can help provide essential nutrients, support your immune system, and aid in recovery.

What should I do if I forget a dose?

Regarding missed doses of Ibritumomab injection, it is crucial to adhere to the prescribed treatment schedule as closely as possible. However, if you happen to miss a dose, it is important to contact your healthcare provider immediately for guidance. They will be able to provide specific instructions based on your situation and determine the best course of action. It is not advisable to try to make up for a missed dose without consulting your healthcare provider first, as they will consider various factors, including the timing of the missed dose and your overall treatment plan.

What side effects can this medication cause?

Ibritumomab injection, like any medication, can cause side effects. It’s important to note that not everyone will experience these side effects, and their severity can vary from person to person. Here are some potential side effects associated with Ibritumomab injection:

• Infusion reactions: Some individuals may experience infusion-related reactions during or shortly after receiving Ibritumomab. These reactions can include fever, chills, nausea, vomiting, headache, dizziness, itching, rash, and difficulty breathing. These reactions can range from mild to severe, and medical attention may be required.
• Bone marrow suppression: Ibritumomab can affect the bone marrow’s ability to produce new blood cells. This can lead to a decrease in white blood cells, red blood cells, and platelets. It may result in an increased risk of infection, anemia, and bleeding.
• Infections: Due to the suppression of the immune system, there is an increased risk of developing infections while undergoing treatment with Ibritumomab. Symptoms of infection may include fever, sore throat, cough, or difficulty breathing. It’s important to promptly report any signs of infection to your healthcare provider.
• Radiation-related side effects: Ibritumomab contains a radioactive substance, yttrium-90, and there is a potential for radiation-related side effects. These may include low blood cell counts, fatigue, and an increased risk of developing certain cancers, such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
• Allergic reactions: Some individuals may experience allergic or hypersensitivity reactions to Ibritumomab. Symptoms can range from mild to severe and may include rash, itching, swelling, dizziness, and difficulty breathing. Immediate medical attention is necessary if such reactions occur.
• Other common side effects: Additional side effects that have been reported with Ibritumomab include fatigue, stomach discomfort, diarrhea, muscle or joint pain, skin reactions, and changes in taste.

It’s important to discuss any concerns or potential side effects with your healthcare provider. They can provide you with more specific information based on your medical history and individual circumstances.

What should I know about storage and disposal of this medication?

• Storage: Ibritumomab injection should be stored as per the instructions provided by the manufacturer or healthcare provider. It is typically stored in a controlled environment, such as a hospital or clinic setting, where proper storage conditions can be maintained. Follow the specific storage instructions given to you, including any temperature requirements.
• Disposal: Proper disposal of Ibritumomab injection is essential to prevent accidental exposure or environmental contamination. It should be disposed of in accordance with local regulations and guidelines for the disposal of hazardous materials. Your healthcare provider or pharmacist can provide guidance on the safe and appropriate disposal method.

In case of emergency/overdose

• Emergency: If you experience a severe allergic reaction or any other emergency while receiving Ibritumomab injection, such as difficulty breathing, chest tightness, swelling of the face or throat, or severe infusion reactions, seek immediate medical attention or call emergency services.
• Overdose: Since Ibritumomab is administered by a healthcare professional, the likelihood of an overdose is low. However, if you suspect an overdose or have any concerns, contact your healthcare provider or seek medical assistance immediately.

What other information should I know?

• Regular follow-up appointments: It is important to attend all scheduled follow-up appointments with your healthcare provider. They will monitor your progress, assess treatment response, and manage any potential side effects or complications.
• Informing other healthcare providers: Make sure to inform all healthcare providers involved in your care, including dentists and specialists, about your Ibritumomab treatment. This is important for coordinating your overall healthcare and ensuring that all providers are aware of any potential interactions or precautions related to the medication.
• Medication interactions: Inform your healthcare provider about all the medications, supplements, and herbal products you are taking, as they may interact with Ibritumomab. Certain medications, such as live vaccines, may need to be avoided or adjusted during treatment.
• Pregnancy and contraception: If you are a woman of childbearing potential, it is important to use effective contraception during treatment with Ibritumomab. Discuss pregnancy planning and contraception options with your healthcare provider.
• Supportive care: Your healthcare provider may recommend supportive measures to manage side effects and optimize your well-being during treatment. This may include medications to manage symptoms, hydration, and lifestyle adjustments.

Always consult your healthcare provider or pharmacist for comprehensive and personalized information regarding the storage, disposal, emergency procedures, and any other specific instructions related to your use of Ibritumomab Injection.